Imunon, Inc. Accrued Investment Income Receivable
Imunon, Inc. (IMNN) had Accrued Investment Income Receivable of $7.87 thousand as of 2020-06-30, per its 10-Q filed 2020-08-14.
Discontinued › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2021-03-19
- 2020-06-30: Accrued Investment Income Receivable $7.87K.
- 2020-03-31: Accrued Investment Income Receivable $22.71K.
- 2019-12-31: Accrued Investment Income Receivable $21.37K.
- 2019-09-30: Accrued Investment Income Receivable $26.97K.
| Period end | Accrued Investment Income Receivable |
|---|---|
| 2020-06-30 | $7.87K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $22.71K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $21.37K 10-K · filed 2021-03-19 |
| 2019-09-30 | $26.97K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $65.67K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $78.07K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $68.31K 10-K · filed 2020-03-25 |
| 2018-09-30 | $76.75K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $56.83K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $67.19K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $54.44K 10-K · filed 2019-03-29 |
| 2016-12-31 | $4.01K 10-K · filed 2018-03-27 |
| 2016-09-30 | $4.52K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $21.00 10-Q · filed 2016-08-15 |
| 2015-12-31 | $26.73K 10-K · filed 2017-03-24 |
| 2015-09-30 | $24.62K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $51.77K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $37.70K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $210.03K 10-K · filed 2016-03-30 |
| 2014-09-30 | $206.17K 10-Q · filed 2014-11-10 |
| 2014-06-30 | $291.15K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $339.79K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $212.05K 10-K · filed 2015-03-12 |
| 2013-09-30 | $251.30K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $206.21K 10-Q · filed 2013-08-08 |
| 2013-03-31 | $283.08K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $65.92K 10-K · filed 2014-03-13 |
| 2012-09-30 | $133.55K 10-Q · filed 2012-11-09 |
| 2011-12-31 | $243.75K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |